|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
Kiran Mazumdar-Shaw's first company
|
|
gptkbp:awards
|
Best Biotech Company 2019
Frost & Sullivan Award 2020
|
|
gptkbp:ceo
|
gptkb:Kiran_Mazumdar-Shaw
|
|
gptkbp:clinical_trial
|
Phase III trials
Phase I trials
Phase II trials
|
|
gptkbp:collaboration
|
gptkb:Harvard_University
gptkb:University_of_California
gptkb:MIT
|
|
gptkbp:community_engagement
|
Education programs
Health initiatives
Skill development programs
Women empowerment initiatives
|
|
gptkbp:employees
|
over 11,000
|
|
gptkbp:focus
|
gptkb:Research_and_Development
Biopharmaceuticals
Generics
Novel biologics
|
|
gptkbp:founded
|
gptkb:1978
|
|
gptkbp:founder
|
gptkb:Kiran_Mazumdar-Shaw
|
|
gptkbp:has_research_center
|
gptkb:Bangalore
gptkb:Malaysia
gptkb:USA
|
|
gptkbp:headquarters
|
gptkb:Bangalore,_India
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Biocon Limited
|
|
gptkbp:industry
|
gptkb:biotechnology
Pharmaceuticals
|
|
gptkbp:invention
|
biopharmaceuticals
biosimilars
over 100 patents
insulin products
|
|
gptkbp:investment
|
$50 million in expansion
$200 million in R& D
$100 million in manufacturing
|
|
gptkbp:market
|
gptkb:India
Global
|
|
gptkbp:partnership
|
gptkb:Mylan
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Sandoz
|
|
gptkbp:products
|
gptkb:diabetes
gptkb:Biosimilars
Enzymes
Monoclonal antibodies
|
|
gptkbp:revenue
|
$1 billion (2021)
|
|
gptkbp:social_responsibility
|
gptkb:Philanthropy
CSR activities
|
|
gptkbp:stock_exchange
|
gptkb:BSE
NSE
|
|
gptkbp:subsidiary
|
Syngene International Limited
|
|
gptkbp:sustainability
|
Energy efficiency programs
Green initiatives
Waste management programs
Water conservation efforts
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.biocon.com
|
|
gptkbp:bfsParent
|
gptkb:Kiran_Mazumdar-Shaw
|
|
gptkbp:bfsLayer
|
5
|